Published On: Tue, Oct 7th, 2014

Aethlon Medical, Inc. (OTCMKTS:AEMD): Blogged About a Pivotal 2009 Moment That Redefined CTE Research

Aethlon Medical, Inc. (OTCMKTS:AEMD)’s Chairman and CEO, James Joyce, today published a blog post on He highlighted a 2009 moment as an inflection point that possibly redefined CTE research and the way many sports respond to head injury. He also noted that the moment also inspired the company’s DETECT study in collaboration with the Boston University CTE Center and Exosome Sciences, Inc. Joyce also wrote about the company’s research effort to identify and monitor CTE in living individuals through DETECT study.

A press conference conducted at the BU CTE Center in 2009 during the Super Bowl XLIII helped transform research into CTE, which was once considered not well-defined condition. The Boston University team announced that NFL veteran Tom McHale was suffering from CTE. The common history of people suffering from this condition was a history of severe head trauma and multiple concussions. He also memorized how Tom McHale’s death inspired this research to develop a blood-based diagnostic agent. He updated that BU CTE Center enrolled former NFL players in the DETECT study.

Aethlon Medical, Inc. (OTCMKTS:AEMD) is engaged in development of medical devices, targeting unmet clinical needs in the areas of cancer, infectious disease and neurodegenerative disorders. Aethlon’s lead portfolio candidate Hemopurifier® selectively targets the rapid elimination of tumor-secreted exosomes responsible for tumor progression. Aethlon holds majority control in Exosome Sciences, which is furthering exosome-based diagnostics and monitoring agents for cancer and other conditions.

Mr. Joyce is the founder of Aethlon Medical, Inc. (OTCMKTS:AEMD). Prior to that, he was CEO of James Joyce & Associates since February 1993. Mr. Joyce is a University of Maryland graduate and also a founder of Mission Labs, Inc. At Aethlon, he led the transformation of the concept of a selective therapeutic filtration device for the treatment of hepatitis C and HIV patients.

© Copyright 2016 OTC News Magazine. All rights reserved.